THE EXISTENCE of an immune response to tumour antigen has been demonstrated for several animal systems. This response is most often studied in terms of humoral parameters (Negroni & Hunter, 1971; Robertson & Black, 1969) but evidence for the presence of cytotoxic T lymphocytes (CTL) has given rise to a cellular approach to this same phenomenon. This approach has been particularly exploited in viral-murine systems (Levy & Leclerc, 1977) which have demonstrated raised T-cell cytotoxicity within a syngeneic context.
However, "little information is available that would allow one to determine whether the in vitro phenomena are relevant to in vivo tumour rejection" (Levy & Leclerc, 1977) . The situation is even more obscure for transplantation of non-producer tumour cells. We have studied a model of this latter type, testing the in vitro activity of splenocytes and sera from transplanted mice which had never shown tumour rejection, as well as from mice immunized by different techniques. Correlation with in vivo protection was investigated by the Winn assay and the challenge inoculation of immunized mice.
We were able to show that, within a defined context, CTL were capable of tumour-cell lysis in adoptive transfer, and lines of evidence suggested that the CTL were responsible for tumour rejection in the challenged animal. But in other situations, in-vitro-effective CTL acted as nonprotectors in vivo. Different responses were related to different modes of immunization. The best circumstance for an anti-tumour response was associated with early surgical removal of a small number of transplanted tumour cells. The unaltered limited amount of antigen appeared responsible for the induction of effective CTL, whereas transplantation without surgical removal led to overwhelming numbers of multiplying tumour cells, and immunization by irradiated cells led to a more complex and less protective response, possibly because of the repeated injection of modified antigen.
MATERIALS AND METHODS

Experimental system
The animals used in this study were 5-6-week-old C57BL/6 female mice. Our MBL2 tumour originated from a lymphosarcoma which was induced by Moloney virus (MSV) in C57BL/6 females (Glynn et al., 1968) . This line was maintained and continued in its ascitic form by i.p. injection of 106 viable MBL2 cells. If 5 x 104 cells were injected s.c. into the rear thigh, a solid tumour appeared which was consistently lethal on Days 20-25 after inoculation.
In our laboratory, this line does not appear to be accompanied by viral propagation. This was ascertained after inoculating D56 (S+L-) cells with a cell filtrate from MSV-bearing MBL2 cells. Since the inoculation did not result in transformation of the D56 (S+L-) strain (Prof. C. Jasmin, ICIG, Villejuif, France) we concluded that the MBL2 cells do not support propagation of the virus. An EL4 tumour line derived from benzanthracene-induced lymphoma in C57BL/6 male mice were used to test the specificity of our results.
In vitro tests
T-type cytotoxicity.-Target cells were MBL2 and effector cells were a total splenocyte population containing CTL. The technique has previously been described by Cerottini & Brunner (1971) and consists of incubating splenocytes at different ratios (10/1 to 100/1) with 104 target cells labelled with chromium 51 (51Cr-S1, Saclay). This mixture was incubated for 3 h at 37°C followed by 1 h at 45°C (Dunkley et al., 1974) . Results are expressed as percentage specific cytotoxicity + s.d.
Secondary MLTC-CML.-Lymphocytes which had been sensitized in vivo were subsequently stimulated in vitro to produce CTL in mixed culture with tumour cells (MLTC). Cultures were carried out in 30ml flasks (25100 Corning CML) containing 40x 106 splenocytes and 8 x 106 irradiated MBL2 cells (60 Gy, 60Co source, Gammatron III, Siemens) both of which are suspended in 20 ml of medium previously defined by Cerottini et al. (1974) .
Cytotoxic activity of killer cells (ADCC).-Target cells were CRBC coated with rabbit anti-CRBC antibody. Effector cells were the entire splenocyte population. The technique was that of Ghaffar et al. (1976) . Briefly, 104-labelled CRBC were coated with anti-CRBC serum at selected dilution and incubated for 18 h at 37°C with splenic cells in variable proportions (10/1 to 100/1). Anti-serum was prepared using the Hunninghake & Fauci method (1976) . Results are expressed as percentage specific cytotoxicity ± s.d.
Lymphocyte-dependent antibody (LDA). Before undertaking this test, the absence of Fc receptor on MBL2 target cells was demonstrated by the EA-rosette technique which showed 2-3% rosettes (Thierry et al., 1976) .
The LDA technique is the same as that used to measure K-cell activity, but with the following modifications for effector and target cells: target MBL2 cells are coated with test serum at different dilutions (1/20 to 1/200). Mouse splenocytes or, even better, human lymphocytes (which are an excellent source of K cells, Wyss & Cerottini, 1976) were used as effector cells. We tried to eliminate false negative reactions due to Ag-Ab complexes by pre-incubating the test sera with polyethylene glycol (PEG) (Creighton et al., 1973) .
Complement (C')-dependent antibody (C'DA). -MBL2 target cells were exposed to normal and experimental mouse serum plus C' (guinea-pig, Gibco). The test procedure followed the technique described by Wernet & Lilly (1975) . Briefly, 106 51Cr-labelled MBL2 cells were incubated at 37°C in test serum at different dilutions (1/4 to 1/640) in the presence of C' for a predetermined time (1, 2 and 3 h). Sera were also tested after PEG incubation (Creighton et al., 1973 (Leclerc et al., 1973) . Anti-Thy 1-2 serum was used (with C' guinea-pig, Difco) to identify the cytotoxic T lymphocytes. Table I summarizes the different techniques, with an indication of the test schedule.
Immunization techniques
Amputation.-Mice were anaesthetized and the leg receiving the inoculum was amputated before the onset of metastasis. Histopathological examination established this to be before Day 20 post-inoculation, though local ganglia involvement can already be demonstrated on Day 8. The difficulty with this procedure is that the tumour-cell inoculum is injected s.c. and often the tumour will develop in the inguinal region. It is therefore necessary to excise all suspected tissue (especially local nodes) in order totally to eliminate the inoculum and prevent tumour recurrence. 50% of the amputated tumourbearing mice survived and showed no evidence of tumour.
Immunization by i.p. injection of MBL2 cells treated with mitomycin-C (MTC-MBL2).
-The protocol was that of Benjamini et al. (1977) as modified by Thiery & Serrou (1974) in order to use the optimal dose of mitomycin C (MTC-Ametycine, Choay) necessary to block MBL2 cells without causing lysis. Cell multiplication was at its lowest point and cell mortality was not more than 15% when 20 ,ug of MTC was used to effectively block 106 MBL2 cells suspended in 100 ,ul of culture medium. Cell viability was verified by trypanblue exclusion.
Immunization by i.p. injection of irradiated MBL2 cells.-The technique was that described by Carlson & Terres (1976) . Briefly, mice were injected s.c. with 5 x 106 MBL2 irradiated cells (100 Gy) in FCA. This inoculation was followed by 5 i.p. booster injections also containing 5 x 106 irradiated MBL2 cells, but no FCA.
In vivo tests
Challenge.-The challenge consisted of s.c.
injection of tumour inoculum into immunized C57BL/6 females. A lethal tumour consistently appeared in non-immunized mice.
Winn assay.-Cytotoxic T effectors were transferred according to the Winn assay technique (1961) . Briefly, normal C57BL/6 females are injected with tumour inoculum plus sensitized mouse splenocytes in different proportions (30/1; 100/1; 300/1).
RESULTS
Positive cell-mediated cytotoxicity was obtained in every case. ADCC was equal in all groups (mice, control, tumoral and immunized mice) by the various methods. These observations were therefore regarded as uninformative. Humoral cytotoxicity was always negative; tests for LDA antibodies were negative in all cases studied; for both murine or human effector cells C'DA antibodies were demonstrated only after immunization by irradiated cells, and the results will be given in the corresponding section. (Fig. 2) . In one-half of all animals studied, this type of immunization (----). Results of 3 exp. where splenocytes were pooled from 5 immunized mice, one w-eek after the last booster injection.
led to a slight retardation of tumour growth, which increased survival by a few days. IV'inn assay.-Tumour developed in the experimental animals and the control group at the same rate.
In vitro tests after imnmunization w.ith irradiated MBL2 cells Cytotoxicity. Direct cytotoxicity reached 25% for the 100/1 ratio (Fig. 5A ). This cytotoxicity is Ag-specific and T-cellassociated, but did not respond to secondary stimulation. Humoral cytotoxicity (C'DA). C'DA was noted following the addition of C' to experimental mouse serum (Fig. 5B) .
In vivo tests after immunization by i.p. injection of irradiated MBL2 cells
Challenge. Immunization with irradiated MBL2 cells totally protected 66%
of the animals (Fig. 2) . Seventeen per cent of the mice showed moderate immunity (survival up to 50 days) while the remaining mice showed no apparent protection after irradiated-cell administration. The immunization noted for these mice was not altogether specific; when they were challenged with EL4 cells, they showed retarded tumour growth (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) days longer than the control group) but none of the mice survived the challenge.
Winn assay.-There was a 33% survival rate for the 300/1 group (Fig. 6) In addition, comparison of the data obtained after immunization following surgical removal of the tumour with those after multiple injections of irradiated cells strongly suggested that, in the precise context of the former immunization, CTL were fully capable of cancer-cell lysis in a situation of adoptive immunity, and very probably were responsible for rejection of tumour challenge. Although host protection was seen after immunization by injection of irradiated MBL2 cells, its characteristics differed from that in the amputation group. To begin with, the protection was not total: 66% rejected tumour-cell challenge and 33% for the 300/1 ratio rejected the tumour cell inoculum in the Winn assay (compared with 100% protection in the amputation group for both challenge and Winn assay). Moreover, rejection was not tumourspecific and the Winn assay was not entirely T-cell dependent. Although this method offered significant protection of the animal, it was less informative for the identification of the effector involved.
SIGNIFICANCE OF CTL AFTER VARIOUS IMMUNIZING PROCEDURES
Indeed in the transfer, CTL are associated with different lymphocyte and monocyte populations, particularly macrophages and/or antibody-synthesizing B lymphocytes. And we know that there are protective antibodies, since we showed that this immunization induced C'DA.
In view of these results several questions arise: (i) Why are some CTL not in vivo protectors, since in vitro they behave like in-vivo-protective CTL from amputed mice? (ii) How to account for the difference in response between immunization by amputation and that arising after injection of irradiated cells? And (iii) To what extent are CTL implicated in challenge rejection when it occurs?
The following comments seem relevant:
(i) CTL in the tumour-bearing mice were unable to protect against tumour evolution. This could be due to a disequilibrium in the number and rate of multiplication of protector cells, favouring the increasing number of tumour cells.
Nevertheless, this point is weakened by the fact that a favourable ratio (300/1) in the Winn assay still does not stop tumour growth. Thus other factors than an overwhelming number of tumour cells are needed to explain why these CTL failed to arrest tumour evolution. Possibly the environment encountered by these CTL impeded target-cell recognition, either by excess antigen acting as blocking factor (Gerber & Brown, 1973) or antigen modification due to necrosis within the tumour mass. Alteration of the antigen and its repercussions on in vivo CTL recognition may also be evoked to explain the in vivo failure of MTC-MBL2-immunized CTL to protect against tumour challenge or to yield favourable results in the Winn assay. Although a certain level of recognition was obtained in vitro (Fig. 4A ) it was not enough for challenge rejection or for elimination of tumour cells in the Winn assay.
(ii) Again it appeared that altered antigen and large quantities of antigen are the most plausible explanation for the discrepancy between amputation (T-dependent and antigen-specific absolute protection) and irradiated cell (not entirely Tdependent and antigen-specific and offering only partial protection) immunization Other studies support our findings for secondary response induction : Dunlop et al. (1977) have shown that sensitized precytotoxic lymphocytes were already specifically committed to respond to a second stimulation. Cerottini et al. (1974) Fitch et al. (1975) suggest that cytolysis of the stimulating cell population by the already cytotoxic responder cells may condition a noresponse situation. Ting et al. (1976b) found that the absence of secondary response was associated only with progressor animals (Friend virus) and deduced that only those animals with a strong immune reaction were capable of mounting a secondary response. Our results with irradiated-cell immunization contradicts the Ting hypothesis, since our immunized animals presented a strong immune response, and yet failed to respond after MLTC or ConA stimulation. For this reason, the Macdonald and/or Fitch hypotheses should be kept in mind when considering the case in hand. Of these two hypotheses we tend to prefer the first, since pre-killers, mature effectors and memory cells were shown (Macdonald et at., 1974b) to exist in different stages of cellular differentiation, where precursors and memory cells are high-density small lymphocytes and effectors are characterized as large, lower-density lymphocytes.
Possibly only dense small lymphocytes develop a secondary response.
(iii) If we compare the data after immunization following amputation and after multiple injections of irradiated cells, we can reasonably assume the active role played by CTL in the in vivo rejection of tumour cells, at least in the former case. Previous studies (Ting et al., 1976a; Glaser et al., 1976) (Pioch et al., 1979) that our system did not possess natural killers against MBL2 target cells, and that when non-Tkiller cells were induced after BCG treatment they were not protective in the Winn assay. Formal proof would require the use of more purified populations (i.e. obtained after cloning or positive selection using Lyt 2 antiserum) on one hand, and systemic injection on the other.
The data reported here provide several lines of evidence which strongly suggest that: (a) CTL may be actually specifically and exclusively involved in tumour rejection, within a well-defined context; and (b) nevertheless, different tumour situations may benefit from less specific immunotherapies involving other factors of the immutne response.
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